Page last updated: 2024-08-24

topotecan and gefitinib

topotecan has been researched along with gefitinib in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (63.16)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hayakawa, Y1
Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC1
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H1
Bai, F; Houghton, PJ; Johnston, B; Leggas, M; Panetta, JC; Schuetz, JD; Sorrentino, B; Stewart, CF; Zhou, S; Zhuang, Y1
Fraga, CH; Hagedorn, N; Hubbard, KE; Panetta, JC; Stewart, CF; Waters, CM; Zhuang, Y1
Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM1
Geoerger, B; Gerstenmeyer, A; Lagodny, J; Niemeyer, CM; Odenthal, E; Rössler, J; Vassal, G1
Carcaboso, AM; Elmeliegy, MA; Hubbard, KE; Panetta, JC; Shen, J; Stewart, CF; Tagen, M; Waters, CM; Wynn, HG1
Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP1
Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM1
Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P1

Reviews

2 review(s) available for topotecan and gefitinib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
    American journal of clinical oncology, 2012, Volume: 35, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan

2012

Other Studies

17 other study(ies) available for topotecan and gefitinib

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity

2010
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
[Structure-activity relationship analysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine

2004
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan

2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer research, 2005, Aug-01, Volume: 65, Issue:15

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan

2006
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
    Cancer research, 2006, May-01, Volume: 66, Issue:9

    Topics: Absorption; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Interactions; Female; Gefitinib; Humans; LLC-PK1 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Mucosa; Quinazolines; Swine; Topotecan

2006
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
    Cancer research, 2006, Dec-01, Volume: 66, Issue:23

    Topics: Administration, Oral; Algorithms; Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Proteins; Blood-Brain Barrier; Brain; Central Nervous System; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Gefitinib; Immunohistochemistry; Injections, Intravenous; Mice; Mice, Inbred C57BL; Microdialysis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Time Factors; Topotecan

2006
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
    Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:11

    Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome

2007
EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.
    Anticancer research, 2009, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Blotting, Western; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mutation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured

2009
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Cancer research, 2009, Jul-15, Volume: 69, Issue:14

    Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Blood Proteins; Blood-Brain Barrier; Brain; Cell Line, Tumor; Gefitinib; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microdialysis; Protein Binding; Quinazolines; Tissue Distribution; Topotecan

2009
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome

2010
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
    Cancer research, 2010, Jun-01, Volume: 70, Issue:11

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays

2010